Q-omics provides the consensus-scored SEC14L5 profile across patient tissues and cancer cell-line models. SEC14L5 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, SEC14L5 is differentially expressed in 15, with the highest sampling consensus in HNSC. Additionally, SEC14L5 RNA expression shows 16,384 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight HNSC, and KIRP as cancer lineages where SEC14L5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SEC14L5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SEC14L5 survival associations across molecular data types. SEC14L5 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (11). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SEC14L5 RNA expression–survival associations across cancer types. High SEC14L5 expression shows unfavorable associations in KIRC, but favorable associations in HNSC, UVM, LUSC, LUAD and ESCA. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for SEC14L5 RNA expression.
This table summarizes SEC14L5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for SEC14L5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SEC14L5 shows lower tumor expression in HNSC, COAD, THCA, READ, BRCA and KIRC. The HNSC box plot shows higher SEC14L5 RNA expression in normal versus tumor tissue (log2 FC = −0.831, t-test p < 0.001).
This table shows molecular features associated with SEC14L5 in patient tissues and cancer cell lines. In patient samples, SEC14L5 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, SEC14L5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and LUNG_SCLC.
